Literature DB >> 11308152

Change of c-Myc expression and cardiac hypertrophy in patients with aortic valve replacement.

S Taketani1, Y Sawa, H Ichikawa, S Ohtake, M Nishimura, N Kawaguchi, H Matsuda.   

Abstract

BACKGROUND: Long-term volume overload to the left ventricle (LV) due to aortic regurgitation (AR) tends to cause severe impairment in LV function that cannot be reversed even with aortic valve replacement (AVR). Recently, we reported that the protooncogene c-myc is related to the onset of the cardiac hypertrophy and LV dysfunction in patients with chronic AR. However, it is still unclear whether c-myc is related to reversibility of the cardiac hypertrophy or LV dysfunction after AVR. METHODS AND
RESULTS: Twenty patients with isolated chronic AR who underwent AVR were included in this study. LV function was calculated before and after AVR. After AVR, end-systolic volume index (ESVI) and enddiastolic volume index (EDVI) were improved, but not mass index (LVMI). However, normalization of ESVI and EDVI was observed only in 12 and 9 patients, respectively. Preoperatively, c-Myc protein was expressed in the myocardium of 16 out of 20 patients with an average point count of 35+/-30%. After AVR, c-Myc protein was observed only in 2 patients. Preoperative ejection fraction (EF), ESVI, and postoperative end-systolic stress (ESS)/ESVI had significant correlation to postoperative cell diameter (CD). Percent c-Myc protein expression before the operation was significantly correlated to postoperative CD, ESVI, and ESS/ESVI. Average c-Myc expression was higher in patients who showed normalization of CD and ESS/ESVI after AVR than the patients who did not.
CONCLUSIONS: These data suggest that preoperative expression of c-Myc can be indicative of the reversibility of myocardial cellular hypertrophy and LV dysfunction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11308152     DOI: 10.1016/s0003-4975(00)02656-4

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Transcription Factor 7-like 2 Mediates Canonical Wnt/β-Catenin Signaling and c-Myc Upregulation in Heart Failure.

Authors:  Ning Hou; Bo Ye; Xiang Li; Kenneth B Margulies; Haodong Xu; Xuejun Wang; Faqian Li
Journal:  Circ Heart Fail       Date:  2016-06-14       Impact factor: 8.790

2.  C-Myc induced compensated cardiac hypertrophy increases free fatty acid utilization for the citric acid cycle.

Authors:  Aaron K Olson; Dolena Ledee; Kate Iwamoto; Masaki Kajimoto; Colleen O'Kelly Priddy; Nancy Isern; Michael A Portman
Journal:  J Mol Cell Cardiol       Date:  2012-07-22       Impact factor: 5.000

Review 3.  c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?

Authors:  Claudio Napoli; Lilach O Lerman; Filomena de Nigris; Vincenzo Sica
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

4.  Mitochondrial Creatine Kinase Attenuates Pathologic Remodeling in Heart Failure.

Authors:  Gizem Keceli; Ashish Gupta; Joevin Sourdon; Refaat Gabr; Michael Schär; Swati Dey; Carlo G Tocchetti; Annina Stuber; Jacopo Agrimi; Yi Zhang; Michelle Leppo; Charles Steenbergen; Shenghan Lai; Lisa R Yanek; Brian O'Rourke; Gary Gerstenblith; Paul A Bottomley; Yibin Wang; Nazareno Paolocci; Robert G Weiss
Journal:  Circ Res       Date:  2022-02-03       Impact factor: 17.367

5.  c-Myc Alters Substrate Utilization and O-GlcNAc Protein Posttranslational Modifications without Altering Cardiac Function during Early Aortic Constriction.

Authors:  Dolena Ledee; Lincoln Smith; Margaret Bruce; Masaki Kajimoto; Nancy Isern; Michael A Portman; Aaron K Olson
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

6.  Btg2 is a Negative Regulator of Cardiomyocyte Hypertrophy through a Decrease in Cytosolic RNA.

Authors:  Yuki Masumura; Shuichiro Higo; Yoshihiro Asano; Hisakazu Kato; Yi Yan; Saki Ishino; Osamu Tsukamoto; Hidetaka Kioka; Takaharu Hayashi; Yasunori Shintani; Satoru Yamazaki; Tetsuo Minamino; Masafumi Kitakaze; Issei Komuro; Seiji Takashima; Yasushi Sakata
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.